A5080046861- Phosphodiesterase function and regulation
- Pharmaceutical studies and practices
- Inflammatory mediators and NSAID effects
- Psoriasis: Treatment and Pathogenesis
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Pharmaceutical Economics and Policy
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Autoimmune and Inflammatory Disorders Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Pregnancy and Medication Impact
- Vitamin D Research Studies
- Peripheral Neuropathies and Disorders
- Sphingolipid Metabolism and Signaling
- Asthma and respiratory diseases
- Systemic Lupus Erythematosus Research
- Anesthesia and Neurotoxicity Research
- Inflammatory Bowel Disease
- Lymphoma Diagnosis and Treatment
- Advanced Steganography and Watermarking Techniques
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Autoimmune Bullous Skin Diseases
- Anesthesia and Sedative Agents
- Peptidase Inhibition and Analysis
- Intensive Care Unit Cognitive Disorders
Jiading District Central Hospital
2024
Bristol-Myers Squibb (Switzerland)
2008-2015
AbbVie (United States)
2013
Medical University of Vienna
2013
ABSTRACTObjective: To evaluate the clinical and biological activity of apremilast in patients with severe plaque-type psoriasis.Research design methods: Apremilast, a phosphodiesterase‑4 inhibitor, inhibits vitro multiple inflammatory factors implicated pathogenesis psoriasis. Patients received 20 mg orally for 29 days. Immunohistological analysis was conducted on lesional-skin biopsies psoriasis-associated inflammatory markers. Lipopolysaccharide-stimulated tumor necrosis factor‑α levels...
Background: This study evaluates the efficacy of dexmedetomidine (DEX) in reducing postoperative delirium (POD) and modulating pro-inflammatory cytokines elderly patients undergoing thoracolumbar compression fracture surgery. Methods: In this randomized, double-blind, placebo-controlled trial conducted from October 2022 to January 2023 at Anting Hospital Shanghai, 218 were randomized into DEX (n = 110) normal saline (NS, n 108) groups. The group received 0.5 µg/kg/h DEX, incidence was...
<h3>Background</h3> Apremilast (APR) modulates a network of pro- and anti-inflammatory mediators. <h3>Objectives</h3> The PALACE 1 study compared the efficacy safety APR with placebo (PBO) in patients active PsA despite prior DMARDs and/or biologics over 24 wks. At wk 24, all were randomized to through 52. <h3>Methods</h3> Patients 1:1:1 PBO, 20 mg BID (APR20), or 30 (APR30). 16, <20% reduction from baseline swollen/tender joint counts re-randomized APR20 APR30 (PBO group), remained on...
<h3>Background</h3> Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. PALACE 1, 2, and 3 compared the efficacy safety of APR with placebo (PBO) in patients active PsA despite prior conventional DMARDs and/or biologics. <h3>Objectives</h3> The overall tolerability was assessed a pooled analysis 3, exposure ≥52 wks. <h3>Methods</h3> Patients were randomized 1:1:1 PBO, 20 mg BID (APR20), or 30 (APR30) stratified by baseline (BL)...
<h3>Background</h3> Apremilast (APR), a PDE4 inhibitor, helps regulate immune responses in psoriatic arthritis (PsA). PALACE 1-3 compared APR efficacy/safety with placebo (PBO) patients (pts) active PsA despite prior conventional DMARDs and/or biologics, including efficacy assessment across multiple aspects of disease. Enthesitis and dactylitis are hallmark features that lead to pain disability. <h3>Objectives</h3> Evaluate the impact treatment over 104 wks on enthesitis pooled analysis 1-3....
<h3>Background</h3> Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response causes joint inflammation and other manifestations of psoriatic arthritis (PsA), including skin disease. <h3>Objectives</h3> Compare efficacy safety APR monotherapy with placebo (PBO) in patients active PsA who were DMARD-naïve for up to 104 weeks. <h3>Methods</h3> Patients randomized (1:1:1) PBO, 20 mg BID (APR20), or 30 (APR30). whose swollen/tender counts (SJC/TJC) had not...
<h3>Background</h3> Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. <h3>Objectives</h3> PALACE 3 compared APR vs placebo (PBO) in patients with active psoriatic arthritis (PsA) and at least 1 ≥2-cm lesion baseline (BL) despite prior DMARDs and/or biologics. <h3>Methods</h3> Patients were randomized 1:1:1 PBO, 20 mg BID (APR20), or 30 (APR30) stratified by BL DMARD use. At wk 16, <20% reduction swollen tender joint counts...
<h3>Background</h3> Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. The PALACE 1, 2, and 3 trials compared the efficacy safety of APR with placebo (PBO) in patients active psoriatic arthritis (PsA) despite prior conventional disease-modifying antirheumatic drugs (DMARDs) and/or biologics. <h3>Objectives</h3> Evaluate impact over 52 weeks on PsA disease activity. <h3>Methods</h3> Patients were randomized 1:1:1 receive PBO, 20...
<h3>Background</h3> Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. PALACE compared the efficacy/safety of APR with placebo (PBO) in patients (pts) active PsA who were DMARD-naïve. <h3>Objectives</h3> Evaluate impact treatment over 52 wks on enthesitis and dactylitis among pts. <h3>Methods</h3> Pts randomized 1:1:1 PBO, 20 mg BID (APR20), or 30 (APR30). <20% reduction from BL SJC TJC at Wk 16 required be re-randomized...
<h3>Background</h3> Apremilast (APR), an oral phosphodiesterase 4 inhibitor, helps regulate immune responses in psoriatic arthritis (PsA). PALACE 3 compared the efficacy and safety of APR with placebo (PBO) patients active PsA, including skin disease, despite prior conventional disease-modifying antirheumatic drugs (DMARDs) and/or biologics. <h3>Objectives</h3> Evaluate treatment over 104 weeks. <h3>Methods</h3> Patients were randomized (1:1:1) to PBO, 20 mg BID (APR20), or 30 (APR30)...
<h3>Background</h3> PALACE 1, 2, and 3 assessed the efficacy/safety of apremilast (APR) in pts with active PsA despite prior DMARDs and/or biologics. <h3>Objectives</h3> Assess weight change from BL 3. <h3>Methods</h3> Pts were randomized 1:1:1 to PBO, APR 20 mg BID (APR20), or 30 (APR30) stratified by baseline DMARD use (yes/no). <20% reduction SJC TJC at Wk 16 required be re-randomized APR20 APR30 if initially continued on their initial dose. At 24, all remaining PBO APR30. The pooled...
<h3>Background</h3> Apremilast (APR), an oral phosphodiesterase 4 inhibitor, helps regulate immune responses in psoriatic arthritis (PsA). PALACE 1 compared the efficacy and safety of APR with placebo (PBO) patients active PsA despite prior conventional disease-modifying antirheumatic drugs (DMARDs) and/or biologics. <h3>Objectives</h3> Evaluate treatment over 104 weeks. <h3>Methods</h3> Patients were randomized (1:1:1) to PBO, 20 mg BID (APR20), or 30 (APR30) stratified by baseline DMARD...
Background Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. PALACE 1, 2, and 3 compared the efficacy safety of APR with placebo (PBO) in patients active psoriatic arthritis (PsA) despite prior disease-modifying antirheumatic drugs and/or biologics. Objectives Assess impact baseline weight body mass index (BMI) on clinical response over 24 weeks a pooled analysis. Methods Patients were randomized 1:1:1 PBO, 20 mg BID (APR20),...
<h3>Background</h3> Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. PALACE compared APR efficacy/safety with placebo (PBO) in patients (pts) active PsA who were DMARD-naïve. <h3>Objectives</h3> Evaluate the impact of over 52 wks on physical function among pts. <h3>Methods</h3> Pts randomized 1:1:1 PBO, 20 mg BID (APR20), or 30 (APR30). <20% reduction from BL SJC TJC at Wk 16 required be re-randomized APR20 APR30 if...
<h3>Background</h3> Apremilast (APR), an oral small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate inflammatory mediators. The PALACE 1, 2 and 3 trials compared APR efficacy safety vs placebo (PBO) in patients with active PsA despite prior DMARDs and/or biologics. <h3>Objectives</h3> overall tolerability was assessed a pooled analysis the PBO-controlled phases 3. <h3>Methods</h3> Safety data from three phase 3, randomized, PBO-controlled, double-blind...
<h3>Background</h3> Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. <h3>Objectives</h3> PALACE 3 compared APR vs placebo (PBO) in patients with active psoriatic arthritis (PsA) and 1 or more ≥2-cm lesion at baseline (BL) despite prior DMARDs and/or biologics. <h3>Methods</h3> Patients were randomized 1:1:1 PBO, 20 mg BID, 30 BID stratified by BL DMARD use. At wk 16, <20% reduction both swollen tender joint counts required...
<h3>Background</h3> Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. PALACE compared the efficacy/safety of APR with placebo (PBO) in patients (pts) active PsA who were DMARD-naïve. <h3>Objectives</h3> Assess safety and tolerability for up 52 wks. <h3>Methods</h3> Pts randomized 1:1:1 PBO, 20 mg BID (APR20), or 30 (APR30). <20% reduction from baseline (BL) SJC TJC at Wk 16 required be re-randomized APR20 APR30 if initially...